Skip to content

CNC

Centene Corporation

NYSEHealth CareHealthcare PlansSnapshot 2026-05-08

$55.96+1.78%
Close 2026-05-08 · 1-day change
The bottom line

As of May 8, 2026, CNC has a composite score of 3.5 and a signal label of "mixed." The score reflects medium confidence at 71.6, with elevated risk due to macro factors such as labor and rates. The top drivers affecting the score include macro labor, macro rates, macro growth, and macro inflation. This analysis is provisional.

Composite +3.5as of 2026-05-08

Price

Daily closes from AlphaVantage. Earnings/event dots are placed inline.

Close 2026-05-08
Daily closes. Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event

Factor signals

Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.

L1

Thesis

is this a strong company over a 1–3 year hold?
F1 · Recent financial performance
weak
Bottom 20% of health care cohort
Why this rank
  • Direction share
    0.18
  • Slope (norm)
    0.41
  • Bonus
    0.00
Operating income, last 4 quarters ($M)
1106-458-69549481
F2 · Value
Loss-making
Earnings yield undefined
Why this rank
Price
$55.96
TTM EPS
$-10.49
Earnings yield
Undefined / loss-making
P/E (TTM)
Undefined / loss-making

Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3

F3 · Earnings quality
fragile
Bottom 10% cash conversion in health care cohort
Why this rank
TTM NI ($M)
3,305
TTM CFO ($M)
154
CFO/NI
0.05
L2

Watch

has something changed worth re-reading?
F4 · Management stability
volatile
Bottom 20% activity in health care cohort· see deep-dive ↓
capital unfriendlyBottom 20% — net capital-unfriendly direction
Earnings setup · pre-print positioning
forward-looking
bullishEPS revised -4.9% / 30d, n=17for period ending 2026-06-30
Why this setup
Consensus revisions

EPS estimate $1.11 → $1.05 (-4.9% / 30d). 5 raised, 8 cut, 17 covering analysts.

Rating actions

2 upgrades, 0 downgrades / 30d, 7 maintained. 35% of analysts rate Buy.

Price target activity

7 PT revisions / 30d. Avg target 11.3% above current price.

Material events

1 positive, 0 negative / 30d. See F4 management tile for the event list.

Transition story with positive analyst positioning — often a turnaround setup.

F4 · Management deep-dive — recent events, stated priorities, guidance track record
2

Stated priorities

3 priorityies extracted from earnings transcripts (as of 2026-05-08).

  1. 1.Achieve EPS greater than $3.00growthbehind7% progressprovisional
    2/6: The Company expects full year 2026 adjusted diluted EPS to be greater than $3.00.
    Why this status

    Stated in 3 of last 3 quarters. The guidance for 2026 EPS is set at greater than $3.00. However, the financials show a diluted EPS of -13.5 in 2025-Q3, indicating limited progress towards this target. The trajectory is behind expectations.

  2. 2.Increase investment and other incomecapital allocationmixed37% progress
    4/28: The Company is increasing its investment and other income expectation by $50 million to $1.45 billion.
    Why this status

    Newly stated in 2026-Q1. The company aims to increase its investment and other income by $50 million to $1.45 billion. This is a new initiative, and its impact on financials is yet to be seen. The status is mixed as it is early in the execution phase.

  3. 3.Increase 2025 revenue guidancegrowthwatchprovisional
    4/25: The Company is increasing its 2025 premium and service revenues guidance range by $6.0 billion.
    Why this status

    Stated in 1 of last 1 quarters. The company increased its 2025 revenue guidance by $6.0 billion. However, revenue in 2025-Q4 was $24.23 billion, down from $49.69 billion in 2025-Q3, indicating a challenging trajectory. The status is watch.

3

Guidance track record

Insufficient guidance history for this ticker.

L3

Position context

how violent might the path be while I hold it?
Risk profile · realized
backward-looking
elevatedworst 12m loss −60%, typical day ±1.5%
Why this risk level

Recent vol — 30d annualized 50%; 252d 72%.

Drawdown — Max 1y −60%. Bad day move −5%.

Beta to sector ETF (XLV) 1.22 over 1y.

Liquidity — score 100/100.

Sub-scores — vol 0/100, drawdown 0/100, beta 78/100, earnings vol .

Sector regime
headwind-15.1%sector vs S&P 500, 60d

via XLV

Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.

AI cycle regime · market-wide
2-axis classifier
HeatingManiaSquallCrisisEarnings →Mood ↑
HeatingE +0.13 · M +0.71
Single-axisCHASEz +2.97+1.285d

Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.

Not investment advice. As of 2026-05-08.

3

What changed

The most important moves since the prior daily snapshot.

  1. No material changes since the prior snapshot.

No material changes since the prior snapshot.

as of 2026-05-08

4

Management scorecard

How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.

Composite31.9 / 100
Capital allocation22
Earnings discipline44
Margin discipline17
Balance sheet49
Guidance credibility
Post-call reaction42

Met or beat guidance 100% of the last 1 guided quarters · 19.1% avg surprise

as of 2026-05-08
4

What management is focused on

Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.

  • #1

    Achieve EPS greater than $3.00

    GrowthNew since 2026-05-04

    Centene aims to achieve an adjusted diluted EPS greater than $3.00 for the fiscal year 2026.

    Behind

    Stated in 3 of last 3 quarters. The guidance for 2026 EPS is set at greater than $3.00. However, the financials show a diluted EPS of -13.5 in 2025-Q3, indicating limited progress towards this target. The trajectory is behind expectations.

    7%
    CEO/CFO:The Company expects full year 2026 adjusted diluted EPS to be greater than $3.00.
    Multiple sourcesSource dated 2026-02-06Stated 3 of last 8 quartersFirst seen 2026-05-04provisional
    Show history (3)
    • 2026-Q1Multiple sources

      The Company expects full year 2026 adjusted diluted EPS to be greater than $3.00.

    • 2025-Q4Multiple sources

      its full year adjusted diluted EPS guidance of greater than $3.00

    • 2025-Q3Multiple sources

      the Company is updating its full year 2025 adjusted diluted EPS forecast to at least $2.00

  • #2

    Increase investment and other income

    Capital allocationNew since 2026-05-04

    Centene plans to increase its investment and other income by $50 million to $1.45 billion.

    Mixed

    Newly stated in 2026-Q1. The company aims to increase its investment and other income by $50 million to $1.45 billion. This is a new initiative, and its impact on financials is yet to be seen. The status is mixed as it is early in the execution phase.

    37%
    CEO/CFO:The Company is increasing its investment and other income expectation by $50 million to $1.45 billion.
    Multiple sourcesSource dated 2026-04-28Stated 1 of last 8 quartersFirst seen 2026-05-04
    Show history (1)
    • 2026-Q1Multiple sources

      The Company is increasing its investment and other income expectation by $50 million to $1.45 billion.

  • #3

    Increase 2025 revenue guidance

    GrowthNew since 2026-05-04

    Centene increased its 2025 premium and service revenues guidance by $6.0 billion.

    Watch

    Stated in 1 of last 1 quarters. The company increased its 2025 revenue guidance by $6.0 billion. However, revenue in 2025-Q4 was $24.23 billion, down from $49.69 billion in 2025-Q3, indicating a challenging trajectory. The status is watch.

    2025 revenue guidance increased by $6.0 billion
    No score
    CEO/CFO:The Company is increasing its 2025 premium and service revenues guidance range by $6.0 billion.
    Multiple sourcesSource dated 2025-04-25Stated 1 of last 8 quartersFirst seen 2026-05-04provisional
    Show history (1)
    • 2025-Q1Multiple sources

      The Company is increasing its 2025 premium and service revenues guidance range by $6.0 billion.

as of 2026-05-08
5

How this stock is priced

Two ways to read price: against peers in the same business, and against the company's own history.

Compared to peers
18higher = cheaper

Looks more expensive than peers.

Compared to its own history
13higher = cheaper

Richer than its own typical valuation.

P/E
25.3x
EV/EBITDA
FCF yield
23.5%

P/E over the last 5 years

67 monthly points
fullas of 2026-05-08
7

How this compares

A side-by-side read on composite, valuation, and risk versus peers.

StockCompositeValuationRisk
CNC
Centene Corporation
+3.5fullelevated
LLY
Lilly (Eli)
+21fullmoderate
JNJ
Johnson & Johnson
+18fulllow
ABBV
AbbVie
+12fairlow
UNH
UnitedHealth Group
+24fairelevated
8

Risk — how this stock moves

What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.

A typical day
How much price usually moves either way.
1.5%
A bad day (95th %ile)
A rough but not unusual down day.
-4.7%
Worst 12-month loss
Deepest peak-to-trough drop in the last year.
-59.9%
Earnings-day move
How much price usually moves on earnings day.
elevatedas of 2026-05-08
9

What could change this view

Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.

Upside triggers
  • If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
Downside triggers
  • If next-quarter guidance is cut (currently RAISED as of 2026-04-28)-16 pts
  • If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
  • If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
  • If rates state reverses from -0.37 (negative) to +0.37 (positive)-2.9 pts
10

Material updates

Recent SEC 8-K filings ranked by likely impact, confidence, and recency.

  1. 2026-04-2811d agoItem 2.02

    shall be deemed to be furnished and not filed: 99.1 Press release of Centene Corporation issued April 28, 2026, as to financial results for the first quarter ended March 31, 2026. EXHIBIT INDEX Exhibit Number Description 99.1* Press release of Centene Corporation issued April 28, 2026 as to financial results for the first quarter ended March 31, 2026 104 Cover page information from Centene Corporation’s Current Report on Form 8-K filed on April 28, 2026 formatted in Inline Extensible Business…

    earnings preannouncementpositivescore 56
  2. 2026-03-241mo agoItem 5.02

    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS Effective March 18, 2026, the Board of Directors (the Board) of Centene Corporation (the Company) appointed Theodore Pienkos, 44, a registered CPA, to serve as the Company's Corporate Controller and Chief Accounting Officer. Mr. Pienkos previously has served as the Company's Deputy Corporate Controller since August 2024. Prior to that, he served as…

    executive changeneutralscore 20
  3. 2026-03-092mo agoItem 8.01

    OTHER EVENTS On March 10, 2026, the Company delivered a notice of partial redemption to redeem on March 25, 2026 (the redemption date) $1,000,000,000 aggregate principal amount of its outstanding 4.25% Notes due December 15, 2027 (the 2027 Notes) in accordance with the terms of the 2027 Notes and the Indenture dated as of December 6, 2019 between the Company and The Bank of New York Mellon Trust Company, N.A. as trustee. Following the redemption, approximately $1,186,664,000 of the 2027 Notes…

    legal regulatorynegativescore 13
  4. 2026-03-092mo agoItem 7.01

    REGULATION FD DISCLOSURE Centene Corporation (the Company) will be presenting at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, at 8:30 a.m. EDT. A simultaneous live audio webcast of the presentation on March 10 will be available at https://event.webcasts.com/starthere.jsp?ei=1753406&tp_key=d357b0a0a7&tp_special=8. A webcast replay will be available following the presentation via the Company's website at www.centene.com, under the Investors section. During t…

    mna activityneutralscore 13
  5. 2026-02-212mo agoItem 7.01

    REGULATION FD DISCLOSURE Members of Centene Corporation's (the Company's) senior management team will meet with investors the week of February 23, 2026. Consistent with the Company's guidance previously provided on February 6, 2026, the senior management team plans to reaffirm the Company's 2026 full year GAAP diluted earnings per share (EPS) guidance of greater than $1.98 and its full year adjusted diluted EPS guidance of greater than $3.00. Non-GAAP Financial Presentation The Company is pro…

    mna activityneutralscore 9
11

Score history

The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.

60 snapshots
Data freshness · As of 2026-05-08 · Macro 2026-05-08 · Sector 2026-05-07 · Fundamentals 2026-02-17 · Price 2026-05-07 · Generated 2026-05-08 · Spec 2.3

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.